Adaptive Biotechnologies Corporation
ADPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $882,612 | $707,478 | $1,088,822 | $3,938,359 |
| - Cash | $47,920 | $65,064 | $90,030 | $139,065 |
| + Debt | $89,387 | $98,772 | $108,002 | $111,740 |
| Enterprise Value | $924,079 | $741,186 | $1,106,794 | $3,911,034 |
| Revenue | $178,957 | $170,276 | $185,308 | $154,344 |
| % Growth | 5.1% | -8.1% | 20.1% | – |
| Gross Profit | $106,877 | $94,723 | $127,399 | $105,043 |
| % Margin | 59.7% | 55.6% | 68.7% | 68.1% |
| EBITDA | -$128,759 | -$189,273 | -$175,210 | -$193,345 |
| % Margin | -71.9% | -111.2% | -94.6% | -125.3% |
| Net Income | -$159,492 | -$225,250 | -$200,191 | -$207,279 |
| % Margin | -89.1% | -132.3% | -108% | -134.3% |
| EPS Diluted | -1.08 | -1.56 | -1 | -1.46 |
| % Growth | 30.8% | -56% | 31.5% | – |
| Operating Cash Flow | -$95,212 | -$156,324 | -$183,945 | -$192,727 |
| Capital Expenditures | -$3,664 | -$10,697 | -$16,349 | -$61,746 |
| Free Cash Flow | -$98,876 | -$167,021 | -$200,294 | -$254,473 |